Does red light therapy work for hair loss? It is a question increasingly asked by people experiencing thinning hair or pattern baldness in the UK. Red light therapy — also known as low-level laser therapy (LLLT) or photobiomodulation — uses specific wavelengths of red or near-infrared light applied to the scalp to potentially stimulate hair follicle activity. Available in wearable caps, handheld combs, and professional clinic devices, it has attracted growing interest as a non-invasive option. This article examines the clinical evidence, the types of hair loss it may help, safety considerations, and how to access it appropriately in the UK.
Summary: Red light therapy (LLLT) may offer modest benefit for some individuals with androgenetic alopecia when used consistently, but evidence remains limited and results vary considerably between individuals.
- Red light therapy uses 630–860 nm wavelengths to potentially stimulate follicle activity by increasing cellular energy (ATP) production via mitochondrial absorption.
- Clinical trials show statistically significant but modest improvements in hair density for androgenetic alopecia, typically after 16–26 weeks of consistent use.
- It is most studied for androgenetic alopecia (pattern hair loss); evidence for alopecia areata and telogen effluvium is limited and preliminary.
- UKCA or CE marking and MHRA registration confirm a device meets safety requirements but do not constitute endorsement of clinical efficacy.
- Red light therapy is not available on the NHS and is not recommended in NICE guidelines; first-line treatments remain topical minoxidil and oral finasteride.
- A GP appointment should be the first step to exclude treatable underlying causes such as thyroid dysfunction or iron deficiency before starting any hair loss treatment.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
What Is Red Light Therapy and How Is It Used for Hair Loss
Red light therapy (LLLT) applies 630–860 nm wavelengths to the scalp to stimulate follicular mitochondria, potentially increasing ATP production and shifting follicles towards the active growth phase.
Red light therapy (RLT), also referred to as low-level laser therapy (LLLT) or photobiomodulation, involves the application of specific wavelengths of red or near-infrared light to the scalp. Devices typically emit red light in the range of approximately 630–680 nanometres and/or near-infrared light in the range of approximately 780–860 nanometres, though exact parameters vary considerably between products. Unlike surgical lasers, these devices do not cut or damage tissue; they deliver low-energy light intended to be absorbed by cells within the hair follicle.
The proposed mechanism of action centres on the absorption of light energy by mitochondria within follicular cells, putatively via a photoreceptor enzyme called cytochrome c oxidase. It is hypothesised that this may increase the production of adenosine triphosphate (ATP) — the cell's primary energy currency — which could in turn stimulate follicle activity, support local blood circulation, and shift hair follicles from the resting (telogen) phase towards the active growth (anagen) phase. These mechanisms remain under investigation and should be understood as proposed rather than definitively established.
RLT is available in several formats for home and clinical use:
-
Laser caps and helmets — wearable devices designed for home use
-
Laser combs and brushes — handheld devices moved across the scalp
-
In-clinic laser hoods — professional-grade equipment used in dermatology or trichology clinics
Session duration and frequency vary by device; users should always follow the manufacturer's Instructions for Use (IFU) rather than relying on generic guidance. It is important to note that RLT is a non-invasive, painless procedure involving non-ionising radiation. It is entirely distinct from ultraviolet (UV) light therapy and does not carry the risks associated with UV exposure. Its use for hair loss has grown in recent years, though it is not currently a first-line treatment recommended by NICE, and the NHS does not routinely offer it for this indication.
Not sure if this is normal? Chat with one of our pharmacists →
| Feature | Details |
|---|---|
| Mechanism of action | Light absorbed by mitochondria via cytochrome c oxidase; proposed to boost ATP, stimulate follicles, shift telogen to anagen phase. |
| Wavelengths used | Red light 630–680 nm; near-infrared 780–860 nm. Exact parameters vary by device. |
| Evidence of effectiveness | Modest, statistically significant increases in hair count for androgenetic alopecia after 16–26 weeks; effect sizes are small. Many studies manufacturer-funded. |
| Hair loss types most likely to benefit | Androgenetic alopecia (best evidence); limited data for alopecia areata and telogen effluvium. Unlikely to help scarring alopecias. |
| Safety and side effects | Generally safe; possible scalp warmth, tingling, temporary shedding, or eye discomfort. Avoid use with active scalp infections, photosensitivity disorders, or in pregnancy. |
| UK regulatory status | Not recommended by NICE; not available on NHS. Home devices should carry UKCA/CE marking; manufacturer must be MHRA-registered. Marking confirms safety, not efficacy. |
| Access and cost | Private clinics (dermatology, trichology) or home-use devices (approx. £200–£800+). Consult a GP or consultant dermatologist before starting treatment. |
What Does the Clinical Evidence Say About Its Effectiveness
Clinical trials and meta-analyses show LLLT produces modest but statistically significant increases in hair count for androgenetic alopecia, though many studies are small, manufacturer-funded, and limited by short follow-up.
The clinical evidence base for red light therapy in hair loss has grown over the past decade, though it remains an evolving and imperfect field. Several randomised controlled trials (RCTs) and systematic reviews have reported statistically significant improvements in hair density and thickness in participants using LLLT devices compared with sham devices. A frequently cited meta-analysis published in Lasers in Medical Science found that LLLT produced modest but statistically significant increases in hair count in individuals with androgenetic alopecia, with measurable results generally observed after approximately 16–26 weeks of consistent use. Effect sizes, however, are typically modest — representing incremental improvements in hair count or density rather than dramatic regrowth.
These findings should be interpreted with appropriate caution. Many studies are limited by small sample sizes, short follow-up periods, variability in device parameters (wavelength, power output, treatment duration), and a lack of standardised outcome measures. A significant proportion of trials have been funded by device manufacturers, which may introduce bias. Blinding participants to active versus sham treatment is also inherently difficult, which limits the ability to fully exclude placebo effects.
In terms of UK regulatory context, home-use LLLT devices placed on the Great Britain market should carry UKCA marking (or CE marking where still applicable under transitional arrangements), and the manufacturer or UK Responsible Person must be registered with the Medicines and Healthcare products Regulatory Agency (MHRA). This registration and marking process confirms that a device meets applicable safety and performance requirements; it does not constitute an endorsement of clinical efficacy by the MHRA. In the United States, the FDA has granted 510(k) marketing clearance to certain LLLT devices, which indicates substantial equivalence to a predicate device for marketing purposes — again, this is not a determination of clinical efficacy.
Overall, the current evidence suggests that red light therapy may offer a modest benefit for some individuals with hair loss, particularly when used consistently over several months. It is unlikely to produce significant regrowth in cases of advanced or scarring hair loss, and results vary considerably between individuals. Patients should approach claims of guaranteed outcomes with scepticism and seek guidance from a qualified healthcare professional before commencing treatment.
Types of Hair Loss Red Light Therapy May Help With
Red light therapy is best evidenced for androgenetic alopecia; it is unlikely to benefit scarring alopecias where follicles are permanently destroyed, and evidence for other types remains preliminary.
Not all forms of hair loss are the same, and the potential benefit of red light therapy varies depending on the underlying cause. The condition most studied in relation to LLLT is androgenetic alopecia — commonly known as male or female pattern hair loss. This is the most prevalent form of hair loss in the UK, affecting a substantial proportion of men from middle age onwards and many women, particularly after the menopause. In androgenetic alopecia, hair follicles gradually miniaturise under the influence of dihydrotestosterone (DHT). RLT does not inhibit DHT and should not be considered an anti-androgenic treatment; rather, it is thought to work by potentially stimulating miniaturising follicles and prolonging the anagen (growth) phase through cellular energy mechanisms.
There is also some limited and preliminary evidence to suggest that RLT may be of benefit in:
-
Alopecia areata — an autoimmune condition causing patchy hair loss; evidence here is inconsistent and more limited than for androgenetic alopecia
-
Telogen effluvium — diffuse shedding often triggered by stress, illness, nutritional deficiency, or hormonal changes; some early data suggest RLT may support follicle recovery, though this remains investigational
-
Chemotherapy-induced alopecia — very early and limited research has explored a potential role; this remains speculative, and scalp cooling (as recommended and available via the NHS) is the established intervention for reducing chemotherapy-related hair loss
Conversely, red light therapy is unlikely to be effective in cases of scarring alopecia (such as lichen planopilaris or frontal fibrosing alopecia), where the follicle has been permanently destroyed by inflammation and replaced with fibrous tissue. No treatment — including RLT — can restore hair growth to areas where follicles have been irreversibly lost.
Red flags requiring prompt medical assessment include: rapidly progressive hair loss; scalp pain, tenderness, redness, pustules, or scaling; hair loss accompanied by eyebrow or eyelash loss; hair loss in children; or any systemic symptoms such as fatigue, weight change, or joint pain. These features may indicate a scarring alopecia, systemic illness, or other condition requiring urgent evaluation by a GP or dermatologist.
Accurate diagnosis of the type of hair loss is essential before commencing any treatment. A GP can assess for underlying medical causes and refer to a consultant dermatologist where appropriate. The British Association of Dermatologists (BAD) and the Primary Care Dermatology Society (PCDS) provide useful guidance on alopecia types and referral pathways.
Safety Considerations and Possible Side Effects
Red light therapy is generally safe with rare serious adverse effects; users with photosensitivity disorders, active scalp infections, suspicious lesions, or who are pregnant should seek medical advice before use.
Experiencing these side effects? Our pharmacists can help you navigate them →
Red light therapy is generally considered safe when used as directed, and serious adverse effects are rare. Devices used for hair loss emit non-ionising radiation at low energy levels; they do not damage DNA and do not carry the carcinogenic risks associated with UV radiation. Clinical studies to date have not identified significant long-term safety concerns with scalp-directed LLLT.
Some individuals may experience mild and transient side effects, including:
-
Scalp warmth or tingling during or after treatment
-
Temporary increase in hair shedding in the early weeks of use — this is sometimes reported anecdotally and attributed to follicle cycling, but it is not well evidenced for LLLT specifically; if shedding is marked or persistent, users should stop treatment and seek medical advice
-
Headache or eye discomfort if the eyes are inadvertently exposed to the light source
Eye safety is an important consideration. Users should avoid directing the light towards the eyes and must follow the manufacturer's IFU carefully. Some devices include or recommend protective eyewear.
Individuals with the following should seek medical advice before using red light therapy:
-
Active scalp infections, open wounds, or active inflammatory skin conditions — treatment should be deferred until these are resolved or controlled
-
A personal history of skin cancer, or any suspicious or undiagnosed scalp lesions — medical clearance is recommended before use; a family history of skin cancer alone is not generally a contraindication, but any concerning scalp changes should be assessed by a clinician
-
Known photosensitivity disorders (e.g., lupus erythematosus, porphyria) or use of photosensitising medicines — certain drugs, including some antibiotics (e.g., tetracyclines), retinoids, and amiodarone, can increase sensitivity to light; users should check the device IFU and seek clinician advice if taking any such medication
-
Pregnancy — there is insufficient evidence to confirm safety during pregnancy, and caution is advised
If hair loss worsens significantly, is accompanied by scalp pain, redness, scarring, or other concerning features, or if there is no improvement after six months of consistent use, patients are advised to consult their GP or a dermatologist for further evaluation.
Anyone who experiences a suspected adverse effect or problem with a medical device should report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.
Accessing Red Light Therapy for Hair Loss in the UK
Red light therapy for hair loss is not available on the NHS; patients can access it privately through dermatology clinics or home-use LLLT devices carrying UKCA or CE marking and MHRA registration.
In the UK, red light therapy for hair loss is not available on the NHS as a routine treatment and has not been evaluated or recommended within a NICE clinical guideline for this indication. Patients seeking this treatment will therefore typically need to access it through private routes.
Private clinical settings — Dermatology clinics, trichology practices, and some aesthetic medicine centres offer in-clinic LLLT sessions. A consultation with a consultant dermatologist is the most reliable route to an accurate diagnosis and evidence-based management plan. Some patients also consult registered trichologists; it is important to be aware that trichology is not a statutorily regulated profession in the UK, so qualifications and standards vary. If consulting a trichologist, look for membership of a recognised professional body such as the Institute of Trichologists or the Trichological Society, and ensure that any serious or uncertain diagnosis is confirmed by a GP or dermatologist. These professionals can rule out treatable underlying causes and advise on whether RLT is appropriate alongside other evidence-based treatments such as topical minoxidil or oral finasteride.
Home-use devices — A range of LLLT caps, helmets, and combs are commercially available in the UK, with prices typically ranging from approximately £200 to over £800. When selecting a device, patients should look for products that:
-
Carry UKCA marking (for devices placed on the Great Britain market) or CE marking where applicable under current transitional arrangements
-
Have a manufacturer or UK Responsible Person registered with the MHRA — this can be verified via the MHRA's device registration database
-
Have published clinical data supporting their specific device parameters (wavelength, power output, coverage area)
-
Provide clear, comprehensible Instructions for Use
The quality and power output of home devices varies considerably, and not all products marketed for hair growth have robust clinical evidence. Patients should be cautious of exaggerated marketing claims, check return and warranty policies, and consult a healthcare professional if uncertain.
For anyone experiencing hair loss, the first step should always be a GP appointment to exclude underlying medical causes — such as thyroid dysfunction, iron deficiency, or hormonal imbalances — which may be directly treatable and, if left unaddressed, will limit the effectiveness of any topical or light-based therapy. The NHS hair loss page and the British Association of Dermatologists (BAD) patient information leaflets provide reliable, accessible information on hair loss types, treatment options, and when to seek further help.
Frequently Asked Questions
How long does red light therapy take to show results for hair loss?
Clinical studies suggest that measurable improvements in hair density or count typically require approximately 16–26 weeks of consistent use. Results vary between individuals, and there is no guarantee of regrowth.
Can I use red light therapy alongside minoxidil or finasteride?
Red light therapy is generally considered compatible with topical minoxidil or oral finasteride, and some clinicians use them in combination. You should discuss any combined treatment plan with your GP or a consultant dermatologist before starting.
Is red light therapy for hair loss available on the NHS?
No — red light therapy for hair loss is not routinely available on the NHS and has not been evaluated within a NICE clinical guideline for this indication. It must be accessed privately, either through a dermatology or trichology clinic or via a home-use device.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
